Colorectal Surgeon Dr. Julio Garcia-Aguilar, MD, PhD (seated) with nurse Kieran Kelleher BSN-RN. Dr. Garcia-Aguilar and the colorectal service at MSK are experts at the watch and wait approach to ...

Neoadjuvant treatment with a programmed cell death 1 (PD-1) inhibitor induces clinical complete response and leads to organ preservation in a high proportion of patients with early-stage, mismatch ...

In locally recurrent rectal cancer, neoadjuvant chemo-reirradiation plus surgery with IOERT showed no grade 4–5 toxicities ...

Use of a neoadjuvant checkpoint inhibitor enabled a high proportion of patients with early-stage mismatch repair-deficient (dMMR) solid tumors to avoid surgery and achieve organ preservation in a ...

Dostarlimab treatment led to complete clinical responses in 82% of patients with dMMR tumors, avoiding surgery for most. Recurrence-free survival at two years was 92%, with a median follow-up of 20 ...

New cancer research pioneered by Memorial Sloan Kettering points to a strong alternative to chemotherapy, surgery and radiation for some forms of cancer. Nearly 80% of patients who suffered from a ...

Neoadjuvant radiotherapy followed by surgery can improve overall survival compared with surgery alone in certain patients with locally advanced rectal cancers, most notably in those with lower rectal ...

A retrospective study of patients with distal rectal cancer at Memorial Sloan Kettering Cancer Center (MSK) has found a higher rate of local recurrence after intersphincteric resection with handsewn ...

Patients with stage 3 colorectal cancer who tested MRD-positive with Signatera after surgery saw a meaningful survival ...

Woman diagnosed with rectal cancer at 29 shares her only symptom, has uterine transposition, a surgery to move her womb ...